What Welldoc does

Welldoc, Inc. is a privately held digital health company founded in 2005 and headquartered in Columbia, Maryland. The company develops an AI-powered cardiometabolic health platform that delivers personalized health coaching and chronic disease management across pre-diabetes, diabetes, hypertension, heart failure, weight management, chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH). Its core technology analyzes 680+ unique metrics across 80 health domains annually per user, is powered by approximately half a billion data points, and integrates with 400+ devices and data sources including CGMs, blood pressure monitors, scales, Apple Health, and Google Health Connect. Welldoc holds 11 FDA 510(k) clearances for its BlueStar/Welldoc Diabetes software as a medical device (SaMD) and has built a patent portfolio of 60-67 patents with 100+ clinical publications supporting an evidence-based approach.

The product portfolio spans FDA-cleared SaMD solutions (Welldoc Diabetes, Welldoc Diabetes Rx with prescription-only insulin dose calculator and Insulin Adjustment Program), wellness modules (Welldoc for Diabetes in Pregnancy, Welldoc Weight Management, Welldoc Cardiometabolic Health), and partner-powered platforms (Lilly Health Personalized Health & Medicine Platform for Zepbound/Mounjaro patients, plus the forthcoming Eversense 365 next-gen app for Senseonics). A dedicated AI Lab, led by Chief AI Officer Anand Iyer (PhD, MBA), advances clinical-grade AI using the company's proprietary Model Development Lifecycle (MDLC) with two-loop testing for safety and efficacy; the SIMON AI assistant provides 24/7 personalized coaching, predictive glucose forecasting, and multimodal recommendations.

Welldoc operates a B2B enterprise SaMD licensing model, monetizing through per-member-per-month (PMPM) arrangements with health plans, pharmacy benefit managers, employers, health systems, life sciences companies, and MedTech firms. The company reports its platform supports 53 million covered lives and maintains strategic enterprise relationships with CVS Health, Eli Lilly, Abbott, Dexcom, Humana, Astellas, Abarca, Allina Health, US Family Health Plan, the Montana Department of Public Health and Human Services, and others. Distribution is exclusively through enterprise channels, with eligible individuals accessing the platform through employer, provider, or health plan program IDs.

Name

Welldoc

Legal name

Welldoc, Inc.

Website

https://welldoc.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Welldoc provides an FDA-cleared, AI-powered cardiometabolic platform for managing diabetes, hypertension, weight, CKD, and MASH. It licenses its software-as-a-medical-device to health plans, employers, health systems, and life sciences companies serving 53 million covered lives.

Ownership category

akta.pro rank

Product category

Digital Health Platform for Cardiometabolic Care

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

• Digital health platform
• Cardiometabolic care software
• FDA-cleared medical device
• AI chronic disease management
• Continuous glucose monitoring integration

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enterprise Software Licensing: Welldoc licenses its AI-powered cardiometabolic health platform to enterprise clients including health plans, health systems, employers, and life sciences companies. The platform is offered as Software as a Medical Device (SaMD) with FDA-cleared functionality. Revenue is generated through per-member-per-month (PMPM) licensing fees based on covered lives, as evidenced by the company's focus on '53 million covered lives' and partnerships with payers.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Welldoc sells an AI-powered cardiometabolic digital health platform licensed to enterprises. The core offering is the Welldoc platform anchored by FDA-cleared Software as a Medical Device (SaMD) products for diabetes self-management and prescription-only insulin dosing, extended through non-FDA cleared modules for weight management (including GLP-1 support), hypertension, heart failure, chronic kidney disease, and MASH. The platform integrates with 400+ devices and data sources to deliver real-time personalized AI coaching to members while connecting care teams and partners across health plans, employers, health systems, and life sciences/MedTech clients.

Product overview

Welldoc offers a unified AI-powered cardiometabolic health platform comprising multiple FDA-cleared and non-FDA cleared products. The core offering includes Welldoc Diabetes (FDA-cleared SaMD for type 1 and type 2 diabetes) and Welldoc Diabetes Rx (prescription-only insulin management with dose calculator and titration support). Weight management and broader cardiometabolic support are delivered through non-FDA cleared wellness modules covering hypertension, heart failure, CKD, and MASH. The platform integrates with 400+ devices including CGMs, blood pressure monitors, scales, and activity trackers. BlueStar, the company's original FDA-cleared digital therapeutic, is now subsumed within the unified Welldoc platform. The platform powers partner solutions including the Lilly Health app and is backed by 11 FDA 510(k) clearances and 60+ patents.

Differentiator

Problem solved

Functional benefit

Brands

• BlueStar: FDA-cleared digital health solution for diabetes management
• Welldoc Diabetes
• Welldoc Diabetes Rx
• Welldoc Rx
• SIMON

Products and services

• Welldoc Diabetes FDA-cleared digital health solution and Software as a Medical Device (SaMD) for diabetes management, providing secure capture, storage, and transmission of glucose data with coaching messages based on real-time glucose values and trends. Supports adults with type 1 and type 2 diabetes, and is one of the company's core offerings with multiple 510(k) clearances.
• Welldoc Diabetes Rx Prescription-only insulin management features built on Welldoc Diabetes. Includes a prescription insulin dose calculator for bolus insulin users with type 1 or type 2 diabetes that calculates doses based on carbohydrates and blood glucose values, and an Insulin Adjustment Program (IAP) for long-acting basal insulin titration in type 2 diabetes, configured by healthcare providers.
• BlueStar FDA-cleared digital therapeutic and the first FDA-cleared Software as a Medical Device for diabetes, guiding individuals through living with diabetes by enabling self-management and enhancing connections to healthcare teams. Now integrated as part of the broader unified Welldoc platform, with an extensive BlueStar patent family.
• Welldoc Weight Management AI-powered weight management solution integrating GLP-1 medication support, behavior change, and data connectivity. Provides personalized daily guidance, nutrition support, medication tracking, and progress tracking for weight goals, designed for use with and without GLP-1 therapies.
• Welldoc Cardiometabolic Health Platform

Quantifiable outcome

• A1C reduction of 3.07% among patients actively logging blood glucose over 6 months (Allina Health case study)
• +6 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability7 records

Feature7 records

Partnerships

15 partnerships are on record, tiered core and minor.

• SenseonicscoreStrategic or Co-development Partner · 10 June 2026Strategic partnership to develop next-generation mobile application for the Eversense 365 implantable CGM system. The new app will add capabilities to enhance user experience and integrate with digital health tools, with U.S. launch expected H2 2026. Leverages Welldoc's AI platform for CGM-informed bolus calculation, medication management, and metabolic tracking features.
• Digital Medicine Society (DiMe)coreStrategic or Co-development Partner · 16 April 2026Founding partner in DiMe's 'Optimizing Direct-to-Patient (DTP) Strategies for Pharma' initiative to establish operational, regulatory, and evidence-based foundations for scaling DTP healthcare models. Coalition includes Wheel, PHIL Inc., Ypsomed, and other digital health companies.
• b.well Connected HealthcoreStrategic or Co-development Partner · 9 April 2026Strategic partnership for interoperability and seamless patient health record access. Welldoc gains access to patient-authorized health data via b.well's 13-step data refinery process, enabling more complete personalized AI-powered insights. b.well connects nearly 2.4 million providers and 350 health plans.
• HumanacoreStrategic or Co-development Partner · 9 April 2026Partnership via b.well Connected Health to enhance health data access for Humana members, aligning with CMS initiatives to promote interoperability.
• NoomminorStrategic or Co-development Partner · 9 April 2026Partnership via b.well Connected Health to connect health records with Noom's digital health solutions, leveraging AI for personalized care.
• AbarcacoreStrategic or Co-development Partner · 16 December 2025Partnership for Better Balance program - AI-powered cardiometabolic care integrated with Abarca's pharmacy benefit management solutions. Focuses on improving chronic condition management using AI technology and clinical decision-making.
• Eli LillycoreStrategic or Co-development Partner · 4 June 2025Welldoc powers the Lilly Health Personalized Health & Medicine Platform for patients prescribed Zepbound (tirzepatide) or Mounjaro (tirzepatide). The platform provides medication logging, reminders, device connectivity, and personalized coaching for cardiometabolic health goals. This is a significant white-label partnership expanding Welldoc's reach in the GLP-1 medication support space.
• Conifer Health SolutionsminorStrategic or Co-development Partner · 1 April 2023Partnership to launch Conifer Connect, an AI-powered digital health application designed to enhance patient engagement through real-time health monitoring and individualized insights.
• Montana Department of Public Health and Human ServicescoreStrategic or Co-development Partner · 1 July 2020Partnership with Montana Diabetes Program and ADCES Montana Coordinating Body to offer BlueStar digital health solution to Commercial, Medicare and Medicaid populations. Program provides accessible care for rural Montanans with diabetes.
• AbbottcoreTechnology or IntegrationDevice integration partnership for CGM and diabetes device connectivity. Abbott is shown as a partner logo on Welldoc's website, indicating ongoing technology integration relationship.
• DexcomcoreTechnology or IntegrationCGM device integration partnership. Dexcom is displayed as a partner logo, indicating technology integration for continuous glucose monitoring connectivity.
• CVS HealthcoreStrategic or Co-development PartnerStrategic partnership for cardiometabolic care. CVS Health is shown as a key partner logo, with collaboration on clinical strategy and health technology initiatives.
• Astellas PharmaminorStrategic or Co-development PartnerPharmaceutical partnership displayed as partner logo, indicating collaboration in digital health solutions for cardiometabolic conditions.
• Association of Diabetes Care and Education Specialists (ADCES)minorStrategic or Co-development PartnerPartnership with ADCES Montana Coordinating Body for diabetes care and education services, supporting the Montana digital health program.
• US Family Health PlancoreStrategic or Co-development PartnerLongstanding partnership implementing Welldoc platform as extension of chronic care program for military retirees and family members of active duty, activated National Guard and Reserves.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Omada Health: Omada Health is a direct peer offering a virtual cardiometabolic care platform for diabetes prevention, diabetes management, hypertension, and weight management sold to health plans and employers via PMPM contracts — directly overlapping Welldoc's enterprise model and target conditions.
• Livongo (Teladoc Health): Livongo (now part of Teladoc Health) pioneered the connected device + AI coaching model for diabetes and hypertension sold via PMPM to payers and employers — historically the closest direct competitor and blueprint for Welldoc's BlueStar model.
• DarioHealth: DarioHealth is a direct peer offering a multi-condition digital therapeutics platform (diabetes, hypertension, weight, musculoskeletal, behavioral) with connected devices and AI coaching sold to payers and employers — overlapping Welldoc's cardiometabolic and multi-condition strategy.
• Virta Health: Virta Health is a direct peer providing AI-guided, clinician-supervised virtual care for type 2 diabetes reversal and metabolic health, sold to payers, employers, and health systems — directly competing for the same cardiometabolic PMPM contracts as Welldoc.
• Vida Health: Vida Health is a direct peer providing virtual chronic-condition management (diabetes, hypertension, weight, mental health) for payers and employers, combining AI coaching with human clinicians — comparable to Welldoc's enterprise cardiometabolic and integrated mental wellbeing offerings.

Emerging players

• Ro (Roman): Ro operates direct-to-patient virtual care including weight management with integrated GLP-1 prescribing and coaching — partially overlapping with Welldoc's GLP-1 companion offering and emerging as a competitor for life sciences and employer partnerships in cardiometabolic care.
• Noom: Noom is a digital health platform with weight management, GLP-1 support, and behavior-change coaching increasingly sold into employer and payer channels — overlapping with Welldoc's weight management and lifestyle modules and now a data-sharing partner via b.well.
• MyFitnessPal: MyFitnessPal is a consumer nutrition and activity tracking platform increasingly integrated into payer and employer wellness programs — adjacent to Welldoc's weight management, nutrition, and lifestyle behavior-change features.

Broad incumbents

• Verily (Alphabet): Verily is a broader Alphabet-owned health technology incumbent developing chronic disease management, AI-driven clinical insights, and care platforms — overlapping with Welldoc at the payer and life sciences intersection, though not focused exclusively on cardiometabolic.

Others

• Dexcom: Dexcom is a CGM device manufacturer and Welldoc integration partner; while not a direct competitor, Dexcom's move into adjacent software/services (e.g., Stelo, Dexcom Clarity integrations) makes it a strategic adjacent player shaping the diabetes data ecosystem Welldoc depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/welldoc
• LinkedInlinkedin.com/company/welldoc-inc
• Facebookfacebook.com/151865238334549

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Welldoc